FUSN - Fusion Pharmaceuticals Inc Stock Price, Fair Value and News

$21.55

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

FUSN Price Action

Last 7 days

0.2%

Last 30 days

0.5%

Last 90 days

79.5%

Trailing 12 Months

328.7%

FUSN RSI Chart

FUSN Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-17.58

Price/Sales (Trailing)

164.95

EV/EBITDA

-21.18

Price/Free Cashflow

-20.91

FUSN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

FUSN Fundamentals

FUSN Revenue

Revenue (TTM)

11.1M

Rev. Growth (Yr)

82.61%

Rev. Growth (Qtr)

53.05%

FUSN Earnings

Earnings (TTM)

-104.3M

Earnings Growth (Yr)

-38.61%

Earnings Growth (Qtr)

-19.49%

FUSN Profitability

EBT Margin

-846.85%

Return on Equity

-43.12%

Return on Assets

-32.2%

Free Cashflow Yield

-4.78%

FUSN Investor Care

Shares Dilution (1Y)

33.23%

Diluted EPS (TTM)

-1.41

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	11.1M	0	0	0
2023	4.0M	6.3M	8.5M	9.5M
2022	826.0K	1.3M	1.7M	2.2M
2021	0	0	0	381.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

CEO	Dr. John F. Valliant Ph.D.
WEBSITE	https://fusionpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	101

Fusion Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Fusion Pharmaceuticals Inc? What does FUSN stand for in stocks?

FUSN is the stock ticker symbol of Fusion Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fusion Pharmaceuticals Inc (FUSN)?

As of Tue Jun 04 2024, market cap of Fusion Pharmaceuticals Inc is 1.83 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FUSN stock?

You can check FUSN's fair value in chart for subscribers.

Is Fusion Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether FUSN is over valued or under valued. Whether Fusion Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Fusion Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FUSN.

What is Fusion Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 04 2024, FUSN's PE ratio (Price to Earnings) is -17.58 and Price to Sales (PS) ratio is 164.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FUSN PE ratio will change depending on the future growth rate expectations of investors.